Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481835 | 0.98 | CYP1A2 (0.48) | HRH3CYP1A2CYP2D6L3MBTL1TDP1 | |
| SCHEMBL481743 | 0.85 | SMN1; SMN2 (0.41) | HRH3CYP1A2SIGMAR1 | |
| SCHEMBL22230354 | 0.71 | LMNA (0.45) | TDP1 | |
| SCHEMBL14909587 | 0.71 | HRH3 (0.40) | HRH3CYP1A2CYP2D6L3MBTL1TDP1 | |
| SCHEMBL481798 | 0.70 | ADRA2A (0.39) | CYP1A2 | |
| SCHEMBL6428656 | 0.69 | HRH3 (0.39) | HRH3CYP1A2CYP2D6L3MBTL1TDP1 | |
| SCHEMBL14305896 | 0.68 | CYP1A2 (0.51) | HRH3CYP1A2CYP2D6L3MBTL1TDP1 | |
| SCHEMBL29520057 | 0.68 | SMN1; SMN2 (0.54) | HRH3ALOX15 | |
| SCHEMBL3933570 | 0.66 | HRH4 (0.39) | HRH3SIGMAR1SLC6A3 | |
| SCHEMBL2897624 | 0.66 | HRH3 (0.46) | HRH3CYP1A2CYP2D6L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306071-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306071-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | HRH3 432/4885CYP1A2 2312/4885CYP2D6 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.